

## Index

### A

- Abecma® (idecabtagene vicleucel) 65, 130
- acceptable quality limit (AQL) 80
- Access Consortium 125, 185
- accreditation 146
- Act on the Safety of Regenerative Medicine (ASRM) 5, 6, 144–145, 146, 159
- adeno-associated viruses (AAVs) 24, 51
  - animal models 40
  - approved products 72, 164
  - first FDA-approved gene therapy 17, 43
  - good practices 125
  - immunogenicity, vector design, and optimization 41
  - key limitations 51
  - manufacturing 25
  - off-target effects 26
  - product types 73
  - vector heterogeneity 42
- adenosine deaminase deficiency (ADA) 11
- adenoviruses 51
- Advanced Regenerative Medicine Institute (ARMI) 76
- advanced therapy investigational medicinal products (ATIMPs) 86
- advanced therapy medicinal products (ATMPs) 207
  - classification of 4, 121, 122
  - criteria for 121
  - definition 215
  - EU GMP guidance 88
  - EU legislation 117–118
  - factors that will be important for success 207
  - hospital exemption 122
  - labeling requirements 61, 88
  - MAA process and timeline 119, 120
  - regulation of 4
  - starting materials 123
  - storage and distribution 86
  - traceability considerations 58
- adverse drug reactions (ADRs) 199
- adverse events
  - delayed 53, 114
  - reporting 155, 197, 198, 199
  - risk assessment 114
  - serious adverse events (SAEs) 197, 198, 219
  - unexpected serious adverse drug reactions (USADRs) 199
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 123
- Alipogene tiparvovec 94
- Alliance for Regenerative Medicine (ARM) 13, 62, 77
- allogeneic cell therapies
  - definition 215
  - logistics of 86, 91, 93
  - manufacturing site concept 93
  - shelf-life 92, 93
  - storage facilities 92, 94
  - supply chain 93
- Altenburger, Ralf 205

- American Society for Testing and Materials (ASTM) 76, 77
- American Society of Gene and Cell Therapy (ASGCT) 13
- Anderson, Steven A. 103
- animal models 39, 52
- annual reports 173
- Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products (FDA) 10
- Asilomar Conference on Recombinant DNA 9
- assays 25
- Association for the Advancement of Blood and Biotherapies (AABB) 59
- Australia 150, 188
- biosecurity requirements 186
  - clinical trials 178
  - Gene Technology Regulations 183
  - Gene Technology Regulator 183, 185
  - Health Technology Assessment (HTA) 186
  - Intergovernmental Gene Technology Agreement 183
  - legislation 177
  - Medical Services Advisory Committee (MSAC) 186
  - medicare benefits schedule (MBS) 186
  - Office of the Gene Technology Regulator (OGTR) 177, 178, 185, 186
  - Pharmaceutical Benefits Advisory Committee (PBAC) 186
  - pharmaceutical benefits scheme (PBS) 186
  - prescription medicines regulation 181–186
  - regenerative medicines sector 177
  - regulatory framework for biologicals 179
  - standards for biologicals 181
  - Therapeutic Goods Administration (TGA) 177, 178, 179
- Australian Biotechnologies Pty Ltd. 180
- Australian Guidelines for Prescription Medicines (ARGPM) 183
- Australian Register of Therapeutic Goods (ARTG) 178
- biological products listed on 180
  - cellular therapies listed on 182
  - gene therapy prescription medicines listed on 186
- autologous cell therapy
- approved products 72
  - challenges 73
  - definition 215
  - Health Canada Policy Position Paper—Autologous Cell Therapy (2019) 134
  - logistics of 86, 90, 91, 92
  - manufacturing controls 72
  - manufacturing site concept 91, 92
  - shelf-life 91, 92
  - supply chain 90
- autologous transplantation 11
- automated systems 76, 77
- automation 75
- Avery, Oswald 3
- AveXis 17
- axicabtagene ciloleucel (Yescarta®) 65, 130, 182
- case study 174
  - marketing authorization approval 164
- ## B
- Bacillus Calmette-Guerin vaccine 72
- batch release 80
- Bauer, Steven 105
- BBM-H901 injection 164
- benefit-risk paradigms 42
- Berg, Paul 9
- bioactivity 68
- Biogen 130
- biological drugs
- cell therapies regulated as 133
  - gene therapies regulated as 134
- biological products
- Australian Register of Therapeutic Goods (ARTG) 180
  - Australian regulation of 179, 183
  - Class 3 180
  - Class 4 178, 180
  - classes in Australia 180
  - definition 133, 179, 215
  - HCT/Ps regulated as 35
  - labelling requirements 181
  - MOA 30
  - risk-based classification of 179
  - standards in Australia 181
  - TGA review pathways 178, 179
- biologics license applications (BLAs) 51
- biologics manufacturing facilities 77, 81
- biopharmaceutical products
- combination products 29–36
  - types classified as regenerative medicine 1

- biosafety 143
- biosecurity 186
- blood and blood products 57
- Blood Directive 2002/98/EC (EUBD) 57, 58, 119
- breakthrough therapy drug procedures 172
- brexucabtagene autoleucel (Tecartus™) 65, 130, 182
- Breyanzi® (lisocabtagene maraleucel) 65
- Brubaker, Scott 104
- Bryan, Wilson 102, 103, 104
- Bush, George HW 14
- Bush, George W. 7, 8, 15
- Byrnes, Andrew 105
  
- C**
- Califano, Joseph 9
- California 15
- California Institute for Regenerative Medicine 16
- Canada
  - approved CGT products 129, 130
  - key regulatory provisions for CGT Products 131
  - other regulatory pathways and programs 138
  - regulatory framework 129–130, 132
  - regulatory pathways for CGT products 131–134
- Canadian Standards Association (CSA) 135
- cancer vaccines 72
- Canniere, Megan Zoschg 205, 206
- Cartagena Act 148, 215
- Cartagena Protocol 143
- Carticel 11, 72
- cartilage, frozen, irradiated 180
- CBER Advanced Technologies Team (CATT) 40
- Celgene 130
- cell and gene therapies (CGTs)
  - accelerated MAA procedures 172
  - approved products 72, 129
  - autologous therapies 72
  - challenges 175
  - CMC readiness 72, 78
  - common features 24
  - critical process parameters (CPPs) 74
  - critical quality attributes (CQAs) 73
  - CTA procedures in China 170
  - current trends 49
  - diverse characteristics of products 72
  - early phase trials 110
  - example products 100
  - first clinical trial in China 163
  - general features 23
  - immunogenicity 26
  - later stage studies 111
  - long-term follow-up 26
  - Lot Release Program 138
  - MAA procedures in China 171
  - manufacturing 25
  - manufacturing controls 71–80
  - market access 174
  - marketing authorization 138
  - notice of compliance with conditions (NOC/c) 138
  - “off-the-shelf” products 72
  - potency tests 55
  - preclinical assessment 51
  - priority review 139
  - product types 73
  - regulation in China 163–175
  - regulation in NZ 188
  - regulatory considerations 51–54
  - regulatory environment in Singapore 191–200
  - regulatory guidance documents 135
  - regulatory pathways in Canada 131–134
  - safety in clinical trials 25
  - suggested points to consider 82
  - technologies 23
- cell banks
  - definition 215
  - master cell banks (MCBs) 218
  - product-specific challenges 73
  - working cell banks (WCBs) 220
- cell-based advanced therapies
  - comparability studies 62
  - critical process parameters (CPP) 62
  - critical quality attributes (CQA) 62
  - cryopreservation of 64
  - delivery systems 68
  - final products 63–68
  - human cell or tissue-based starting materials 57–62
  - regulation of 4
  - release testing 65, 66
  - samples for testing, stability, and retention 66
  - special considerations 57–69

- transport of starting cells or tissue 60–61
- cell-based products 4
- cell or tissue procurement sites 58–59
- cell-processing products 146
- cells, tissues, and organs (CTOs)
  - cell therapies regulated as 131
  - CTO Regulations 129, 130, 131, 132, 135
  - product definition 133
- cell therapy (CT)
  - Australian Register of Therapeutic Goods (ARTG) 182
  - CTA considerations 137
  - definition 164, 215
  - guidelines related to 143
  - registered products 164
  - regulated as biological drugs 133
  - regulated as combination products 134
  - regulated as human CTOs 131
  - special expectations 110
- cell, tissue, and gene therapy products (CTGTGs)
  - Class 1 (lower risk) 192, 193, 194, 196, 198
  - Class 2 (higher risk) 192, 193, 194, 195, 196, 197, 198, 199, 200, 201
  - clinical trial application routes 198
  - dealer's license 200
  - definition 216
  - definition of 191
  - marketing authorization application
    - requirements and process 193–196
  - marketing authorization pathways 192, 193
  - postapproval variations 196
  - postmarketing vigilance requirements 197
  - product consultation 192
  - registration fees and timelines 196
  - registration retention 196
  - regulation in Singapore 191
  - regulatory framework 192
  - risk-based classification of 192
  - special access routes (SARs) 201
- Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 106
- Center for Biologics Evaluation and Research (CBER) 6, 17, 18
  - INTERACT meetings 40, 105
  - meeting formats 106
  - meeting preparation 106
  - meetings 103
  - Office of Blood Research and Review (OBRR) 18
- Office of Cellular, Tissue, and Gene Therapies (OCTGT) 18
- Office of Tissues and Advanced Therapies (OTAT) 6, 16, 18, 49, 104
- Office of Vaccines Research and Review (OVRR) 18
  - organizational structure 103
- Center for Devices and Radiological Health (CDRH) 32
- Center for Drug Evaluation and Research (CDER) 32
- Center for Drug Evaluation (CDE) 164, 165, 170
- Center for Food and Drug Inspection (CFDI) 164, 165
- Centre for Biologics Evaluation (CBE) 130
- Centre for Digestive Diseases Pty Ltd. 180
- Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics (CERB) 130
- Centre for Regulatory Excellence, Statistics and Trials (CREST) 131
- certificate of pharmaceutical product (CPP) 198
- chemistry, manufacturing, and controls (CMC).
  - See also* manufacturing controls
  - CMC readiness 72, 78
  - current trends 54
  - early stage considerations 40
  - EU regulation 120
  - regulations in China 168
  - in Singapore 197
  - US regulation 106
- chimeric antigen receptor natural killer cells (CAR-NKs) 204
- chimeric antigen receptor T (CAR-T) cell therapies 204
  - approved products 72, 164
  - case studies 174
  - definition 216
  - immunogenicity 26
  - off-target effects 26
  - product types 73
  - technologies 23
- China
  - accelerated MAA procedures 172
  - approved gene therapy products 163, 164
  - case studies 174
  - CGT product regulations 163–175
  - CTA procedures 170, 171
  - drug lists 174

- Drug Registration Regulation (DRR) 171
- first clinical trial for CGT products 163
- gene therapy developments 163
- health authorities 165
- investigational new drug (IND) applications 164
- license renewal 173
- local provincial and municipal Medical Products Administrations (MPAs) 165
- MAA procedures 171, 172
- market access 174
- National Health Commission (NHC) 163
- National Medical Products Administration (NMPA) 163
- postapproval change management 173
- regulatory authorities 164, 165
- China Food and Drug Administration (CFDA) 164
- ChondroCelect 4, 120
- chondrocytes (Ortho-ACI) 180, 182
- Clinical Trial Act (Japan) 153, 155
- clinical trial applications (CTAs) 178
  - for cell therapy products 137
  - for CGT products 170
  - in China 170, 171
  - postauthorization changes and activities 137
  - pre-CTA meetings 136
  - requirements for 136
- clinical trial authorizations (CTAs) 198
  - application process 198, 199
  - application requirements 199, 201
- clinical trial certificates (CTCs) 198
- clinical trial in-country representatives 155
- clinical trial notifications (CTNs) 154, 198
  - application process 198, 199
  - application requirements 199, 201
- clinical trials
  - conducted on ethical grounds 153
  - current trends 49
  - design and endpoint validation 43, 44
  - early phase 110
  - EU regulation 119
  - EU requirements 124
  - expanded access (or compassionate use) 153
  - first human trials 11, 16
  - Health Canada requirements 136–137
  - human stem cell guideline 143
  - Japanese guidelines 153
  - later stage studies 111
  - operations in Japan 155
    - Phase 1 trials 49
    - Phase 2 trials 49
    - Phase 3 trials 49
  - phased trials 154
  - pivotal studies 42–43
  - preclinical studies 51
  - preparing for first-in-human studies 39
  - regulation in Singapore 198, 200
  - safety of CGTs in 25
  - US requirements 110
- ClinicalTrials.gov 12, 13, 14
- clinical trials notification (CTN) 178
- Clinton, Bill 6, 14, 15
- cloning
  - current state laws 7
  - evolution of 5–6
  - “Cloning Human Beings” (President’s Council) 8
- clustered regularly interspaced short palindromic repeats (CRISPR)
  - CRISPR-Cas9 24, 73, 207
  - CRISPR-Cas proteins 204
  - definition 216
  - studies with embryos 163
- CMC readiness
  - definition 72
  - key questions to consider 78
  - prior to Phase III or licensing trials 78
- Code of Federal Regulations (US)
  - 21 CFR 600–680 6
  - 21 CFR 1270 4, 14, 15
  - 21 CFR 1271 6, 15, 16, 17, 99
- Collins, Francis 13
- combination products 29–36
  - cell therapies regulated as 134
  - constituent parts 29
  - co-packaged 30
  - cross-labeled 30
  - definition 216
  - examples 30, 31
  - good manufacturing practices (GMPs) 36
  - good tissue practices (GTPs) 36
  - primary mode of action (PMOA) 30
  - regulatory definition 29
  - request for designation (RFD) 32–33
  - single entity 30
  - types 73
  - types of 31

- combined ATMPs (cATMPs)
    - classification 122
    - classification of 4
    - definition 216
    - legal definition 121
  - commercial-scale manufacturing 79–80
  - Committee for Advanced Therapies (CAT) 6, 118, 119, 216
  - Committee for Human Medicinal Products (CHMP) 6, 119
  - common technical document (CTD)
    - electronic (eCTD) 155
    - Module 1 106
    - Module 2 107
    - Module 3 107
    - structure 106
  - Commonwealth Gene Technology Act (Australia) 183
  - comparability 75
  - comparability studies
    - considerations for 62
    - critical elements 75
    - definition of 75
    - design considerations 62
  - Comparable Overseas Regulators (COR) 184
  - complaints 109
  - conditional approvals
    - Japanese conditional expedited approval system 147, 148
    - procedures in China 172
  - constituent parts 29, 30–31
  - consultation meetings
    - with China CDE 170
    - with Japan PMDA 152
    - regulatory science (RS) strategy consultations 152
  - consultation, product 192
  - contained use 124
  - continuous manufacturing 76
  - contract development manufacturing
    - organizations (CDMOs) 79
  - Co-ordination group for Mutual Recognition and decentralized procedures – human (CMDh) 117
  - Council for International Organizations of Medical Sciences (CIOMS) 197
  - Covid-19 pandemic 17, 207
  - Covid-19 vaccines 122
  - critical process parameters (CPPs) 62, 73, 74, 75
  - critical quality attributes (CQAs) 62, 73, 74, 75, 216
  - cryopreservation
    - of cell-based advance therapies 64
    - definition 216
    - excipients 64, 65
    - labeling requirements 67
    - and logistics 91
  - cryoprotectants 64
  - cryostorage facilities 92
  - culture-based mycoplasma testing 66
  - culture-based sterility testing 66
  - Cures 2.0 114
  - current good manufacturing practices (CGMPs)
    - facility strategies 78
    - for combination products 35
  - current good tissue practices (CGTPs)
    - for combination products 35
    - for HCT/Ps 35, 36
  - Current Guidelines on the Regulation of Therapeutic Products in New Zealand 187
  - current trends 49–55
- ## D
- dangerous goods classification 93
  - databases 13
  - dealer's license 200
  - dealings involving intentional release (DIR)
    - licenses 185
  - dealings not involving intentional release (DNIR) licenses 185
  - delayed adverse events 53, 114
  - deliberate release 124
  - delivery systems 68
  - development safety update reports (DSURs) 170
  - device MOA 31
  - devices 133
  - Dickey-Wicker Amendment 6, 14
  - dimethyl sulfoxide (DMSO) 64
  - Directive 2006/17/EC 87
  - Directive 2009/41/EC 119, 124
  - Directive 2009/120/EC 4, 5, 6
  - DiSilva, Ashanti 11
  - distribution 85–96
    - of advanced therapy investigational medicinal products 86
    - of advanced therapy medicinal products 88

EU tissues and cells directives 87  
   of frozen regenerative medicines 94  
 Division of Cellular and Gene Therapies (DCGT) 102  
   definition 216  
   organizational structure 105  
 DNA 3  
 DNA editing 24  
 documentation. *See* common technical document (CTD)  
 Dolly the Sheep 5–6  
 donor eligibility  
   commercial manufacturing strategy 80  
   product-specific challenges 73  
   requirements 58  
   US regulations 108  
 donors 216  
 donor testing  
   Australian requirements 181  
   US requirements 108, 109  
 Drug-Device Combination Products 134  
 drug lists 174  
 Drug/Medical Device Combination Products Policy 134  
 drug mode of action 31  
 Drug Registration Regulation (DRR) 171  
 drugs  
   biological 133, 134  
   product definition 133

## E

Eacho, Melanie 105  
 electronic common technical document (eCTD) 155  
 embryonic stem cells (ESCs)  
   current state laws 7  
   EU regulations 125  
   human (hESCs) 6, 217  
   NIH guidelines 15  
 end-of-phase 1 (EOP1) meetings 104  
 end-of-phase 2 (EOP2) meetings 104  
 engineered stem cells 216  
 environmental assessments 112  
 environmental impact statement (EIS) 112  
 Environmental Protection Authority (EPA) 188  
 Environment Canada 134  
 equipment 80  
 Ethics Committee (EC) approvals 171

ethnic factors 153  
 EudraGMP 198  
 European Agency for the Evaluation of Medicinal Products (EMA) 4  
 European Blood Directive (EUBD) 123  
 European Commission (EC) 4, 6  
 European Directive for Tissues and Cells (EUTCD) 123  
 European Economic Area (EEA) states 117  
 European Heads of Medicines Agencies 117  
 European Medicines Agency (EMA) 4, 117  
   Cell Products Working Party 117  
   Cell Therapies Working Party 119  
   CMC requirements 55  
   definition of somatic cell therapy 23  
   Gene Therapy Working Party 117, 119  
   PRIME scheme 218  
 European Medicines Directive 2001/18/EC 119, 124  
 European Medicines Directive 2001/83/EC 4, 6, 117–118  
 European Tissue and Cells Directive 2004/23/EC (EUTCD) 57, 58, 87, 118  
 European Union (EU)  
   ATMP legislation 117–118  
   GMP for advanced therapy medicinal products 88  
   regenerative medicine history 4  
   regulation of regenerative medicine 6, 19  
   regulatory framework for regenerative medicines 117–126  
   tissues and cells directives 87  
 evidence generation 45  
 exosomes 73  
 expanded access (or compassionate use) 153  
 expedited review  
   Japanese conditional expedited approval system 147, 148  
   US pathways 45  
 ex vivo gene therapy 216

## F

faecal microbiota, frozen 180  
 FDA Amendments Act of 2007 (FDAAA) 12  
 Federal Food, Drug and Cosmetic Act (FD&C Act) 6, 34  
 fetal tissue research 17  
 fibroblasts 72

- finding of no significant impact (FONSI) 112
  - first-in-human (FIH) studies
    - in Japan 154
    - preparing for 39
  - fixed dose combinations 29
  - Food and Drug Administration (FDA). *See* US Food and Drug Administration (FDA)
  - Food and Drug Administration Modernization Act of 1997 (FDAMA) 12
  - Food and Drug Regulations (FDR) 129, 131, 134
  - Food and Drugs Act (F&DA) 129
  - Fosun Kite 164, 174
  - Foundation for Accreditation of Cell Therapies (FACT) 59
  - French Anderson 11
  - fresh finished products 91
  - frozen regenerative medicines
    - logistics 91
    - storage and distribution 94
  - funding 49, 50
  - future directions 203–207
- G**
- Gavin, Denise 105
  - Gendicine 163, 174
  - gene marking 11, 12
  - Gene Technology Act (Australia) 177, 178, 183–185
  - Gene Technology Advisory Committee (GTAC) 187
  - Gene Technology Regulations (Australia) 183
  - Gene Technology Regulator (Australia) 183, 185
  - Gene Therapy Clinical Trial Monitoring Plan 15
  - gene therapy (GT) 10. *See also* cell and gene therapies (CGTs)
    - animal models 39
    - approved products 163, 164
    - Australian Register of Therapeutic Goods (ARTG) 186
    - benefit-risk paradigm 42
    - Cartagena Act for 148
    - CMC requirements 54
    - current trends 49, 50, 51–54
    - definition 23, 164, 216
    - developments in China 163
    - durability 45
    - early stage CMC considerations 40
    - enhanced review 11
    - evidence generation 45
    - example products 100
    - example products recently approved 135
    - first approved products 17
    - first FDA-approved AAV gene therapy 43
    - first human trials 11, 14
    - guidelines for clinical research 143
    - for hemophilia 54
    - immunogenicity, vector design, and optimization 40
    - limitations of understanding 41
    - logistics of 86, 92–94
    - long-term follow up (LTFU) 45, 46, 53
    - long-term safety 112–113
    - microbial vectors 55
    - non-viral vectors 50
    - off-target effects 26
    - patient preference 43–44
    - pivotal studies 42–43
    - preclinical assessment 52
    - preparing for first-in-human studies 39
    - products regulated as biological drugs 134
    - product types 73
    - for rare diseases 54
    - registered protocols 12
    - regulatory considerations 51–54
    - regulatory review 43–44
    - for retinal diseases 54
    - risk assessment 114
    - special considerations 39–47, 111
    - special expectations 109
    - supply chain 95
    - testing vectors 112
    - therapeutic dose selection 41
    - trial design and endpoint validation 43, 44
    - US regulations 107
    - vector heterogeneity 42
    - viral vectors 50
    - in vivo 218
  - gene therapy medicinal products (GTMPs)
    - classification of 4
    - definition 217
    - legal definition 121
    - logistics 92–93
  - genetically modified organisms (GMOs)
    - Australian biosecurity requirements 186
    - Australian regulation of 183



- definition 183, 217
- EU legislation 119
- EU requirements 124
- logistics 92–93
- Genetic Modification Clinical Research Information System (GeMCRIS) 15
- Gene Transfer Safety Symposia 15
- Gentuit 72
- Genzyme 11
- Germany 150
- Gilead 17, 135
- Gilead Sciences 130
- Glybera 94, 120
- Goldring, Basil 104
- good clinical practice (GCP) 198, 217
- good clinical practice (GCP) inspections 199
- good gene, cellular, and tissue-based product manufacturing practice (GCTP) 149
- good laboratory practice (GLP) 150, 217
- good manufacturing practices (GMPs)
  - current good manufacturing practices (CGMPs) 35
  - definition 217
  - EU guidance for ATMPs 88
  - for combination products 36
  - in Japan 149
  - in Singapore 198
- good postmarketing study practice (GPSP) 156
- good tissue practices (GTPs) 57
  - current good tissue practices (CGTPs) 35
  - definition 217
  - for combination products 36
  - reportable deviations 109
  - US regulations 108
- graft-versus-host disease (GVHD) 217
- Griffith, Frederick 3
- Guidance for Industry Points to Consider in Human Somatic Cell Therapy and Gene Therapy (FDA) 10
- Guideline for Human Embryonic Stem Cell Research (National Academies) 8
- Guidelines for Gene Therapy Clinical Studies (Japan) 5
- Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) 9, 13, 14, 17

## H

- Haseltine, William 3
- Hazardous Substances and New Organisms (HSNO) Act (NZ) 188
- Health Canada 130
  - Biologics and Radiopharmaceutical Drugs Directorate (BRDD) 130, 139
  - Centre for Biologics Evaluation (CBE) 130
  - Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics (CERB) 130
  - Centre for Regulatory Excellence, Statistics and Trials (CREST) 131
  - Drug/Medical Device Combination Products Policy 134
  - Food and Drug Regulations (FDR) 129, 131, 134
  - Health Products and Foods Branch (HPFB) 130
  - Lot Release Program 138
  - Medical Devices Regulations (MDR) 129, 131, 134
  - Office of Policy and International Collaboration (OPIC) 131
  - regulatory guidance documents 135
  - requirements for clinical trials 136–137
  - Safety of Cells, Tissues, and Organs for Transplantation Regulations (CTO Regulations) 129, 130, 131, 132
  - Special Access Program (SAP) 139
- Health Canada Policy Position Paper—Autologous Cell Therapy (2019) 134
- HealthNZ 187
- Health Products Act (HPA) 191
- Health Products (cell, tissue, and gene therapy products) Regulations 2021 191
- Health Products (Clinical Trials) Regulations (Singapore) 198
- Health Research Council of NZ 187
- Health Sciences Authority (HSA) 191
  - guidance documents and checklists 193, 196
  - Innovation Office 192
  - Pharmaceutical Regulatory Information System (PRISM) 199
- Health Technology Assessment (HTA) 186
- hematopoietic progenitor cells (HPCs)
  - definition 217
  - procurement sites 59
  - stability 60
- hemophilia, gene therapy for 54

- history of regenerative medicine 3–21
    - country-specific overviews 4
    - development timeline 14–17
  - HIV/AIDS 12
  - homologous use 131
  - hospital exemption 122, 217
  - Human Adult Stem Cells (Prochymal) 130
  - Human Biomedical Research Act (Singapore) 198
  - Human Cell and Tissue Establishment Registration (FDA) 59
  - human cells, tissues, or cellular or tissue-based products (HCT/Ps)
    - approved products 72
    - biological products 35
    - cell or tissue procurement sites 58–59
    - CGTP requirements 35, 36
    - combination products 29–36, 37
    - definition 34, 217
    - donor eligibility requirements 58
    - donor screening requirements 181
    - labeling requirements 60
    - medical devices 36
    - regulation of 4, 15
    - reportable deviations 109
    - Section 351 100
    - Section 361 99
    - starting materials 57–62
    - US regulations 99, 101
  - human embryonic stem cells (hESCs)
    - definition 6, 217
    - Guideline for Human Embryonic Stem Cell Research (National Academies) 8
  - Human Genetic Resource Administration of China (HGRAC) 171
  - Human Research Ethics Committee (HREC) 178
  - human stem cell guidelines 143
  - human trials. *See* clinical trials
  - Hussey, Deirdre P. 103
- I**
- idecabtagene vicleucel (Abecma®) 65, 130
  - Imlygic (talimogene laherparepvec) 183
  - immunogenicity 25, 40, 217
  - individual case safety reports (ICSRs) 155
  - induced pluripotent stem cells (iPSCs)
    - clinical trials with 143
    - definition 217
  - infectious disease testing 58
  - INitial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) 40, 105
  - Innovation Office (Singapore) 192
  - Innovative Licensing and Access Pathway (ILAP) 125, 217
  - inspections 81
    - good clinical practice (GCP) 199
    - on-site evaluation (OSE) 138
  - Institute of Medicine (IOM) 13
  - Institutional Biosafety Committee Registration Management System (IBC-RMS) 13
  - institutional biosafety committees (IBCs) 12, 185
  - institutional review boards (IRBs) 12, 218
  - Intergovernmental Gene Technology Agreement (Australia) 183
  - International Air Transport Association (IATA) 60
  - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) 4
    - CMC requirements 55
    - common technical document (CTD) structure 106
    - definition of comparability 75
    - guidance documents 135
    - ICH E5 Ethnic Factors in the Acceptability of Foreign Clinical Data 153
    - ICH M3(R2) guidance 151
  - International Organization for Standardization (ISO) 76, 77, 90
  - International Safe Transit Association 60
  - International Society for Computed Tomography (ISCT) 76, 77
  - International Society for Stem Cell Research (ISSCR) 144
  - investigational biologic drug products 137
  - investigational medicinal products (IMPs) 88
  - investigational new drugs (INDs) 71
    - animal models 40
    - CMC requirements 54
    - preclinical assessment 51
    - storage and distribution 87
  - investigations 156
  - in vivo gene therapy 218
  - isolators 77

**J**

## Japan

- adverse event reporting 155
- application and review process 155, 156
- clinical trial notification 154
- clinical trial operations 155
- clinical trials 153
- clinical trials conducted on ethical grounds 153
- CMC requirements 55
- conditional expedited approval system 147, 148
- first-in-human (FIH) studies 154
- good laboratory practice (GLP) 150
- good manufacturing practices 149
- guidance documents 157, 159
- guidelines for clinical research 143
- guidelines related to cell therapy 143
- history of regenerative medicine 5
- human stem cell guidelines 143
- legislations 143, 144
- market approval 155
- mutual recognition agreement (MRA) 150
- nonclinical safety studies 151
- patient registration database 159
- postmarketing surveillance (PMS) 156–158
- regulations 6, 19, 143–160
- Japan new drug applications (JNDAs) 155
- Joint Accreditation Committee ISCT-Europe and EBMT (JACIE) 59
- JW Therapeutics 164, 174

**K**

- Kass, Leon 15
- Kymriah® (tisagenlecleucel) 17, 65, 72, 130, 135, 180, 182

**L**

## labeling

- ATMPs 88
- commercial manufacturing strategy 80
- EU tissues and cells directives 88
- GMO shipments 92
- IMPs 88
- of biologicals 181
- of cryopreserved products 67
- of tissue products 60

- shipping labels 88, 92
- laboratory controls 80
- Lamberth, Royce 16
- Laviv 72
- lentivirus 26, 51
  - definition 218
  - product types 73
- licensing
  - biologics license applications (BLAs) 51
  - CMC readiness 78
  - dealer's license 200
  - dealings involving intentional release (DIR) licenses 185
  - dealings not involving intentional release (DNIR) licenses 185, 186
  - Innovative Licensing and Access Pathway (ILAP) 125, 217
  - licensed manufacturers 146
  - MAA license renewal 173
  - OGTR requirements 178
- liquid nitrogen (LN2) 94
- lisocabtagene maraleucel (Breyanzi®) 65
- living drugs 71
- logistics
  - of allogeneic therapies 86, 91, 93
  - of autologous therapies 86, 90, 91, 92
  - frozen and fresh conditions and 91
  - of gene therapies 86, 92–94
  - product-specific challenges 73
  - regulatory framework 86–89
- logistics lanes 85, 87, 96
- long-term follow up (LTFU) 26, 45, 46, 53
- long-term follow up (LTFU) studies 112–113, 169
- long-term safety 112–113
- Lot Release Program 138
- Luxturna (voretigene neparvovec-rzyl) 17, 51, 72, 130, 135, 186

**M**

- MACI 72
- MacLeod, Colin 3
- Malarkey, Mary Anne 103
- manufacturing 1, 24
  - automated systems 76, 77
  - commercial-scale 79–80
  - continuous 76
  - early stage considerations 40

- example platforms 77
  - non-standardized platforms 25
  - optimization 75
  - points to consider 79–80
  - product-specific challenges 73
  - starting materials 25
  - strategies for commercial phase entry 77
  - manufacturing controls. *See also* chemistry, manufacturing, and controls (CMC)
    - appropriate 75
    - establishment 71–80
    - recommended reading 83
    - sequential elements of establishing 75, 76
    - suggested points to consider 82
  - manufacturing facilities
    - accreditation 146
    - CGMP strategies 78
    - commercial manufacturing strategy 80
    - considerations for 81
    - design points 77, 81
    - inspections 81
    - on-site evaluation (OSE) 138
  - manufacturing license 146
  - manufacturing site concept
    - for allogeneic therapies 93
    - for autologous therapies 91, 92
  - market access 174
  - marketing authorization application (MAA)
    - accelerated approval procedures 172
    - breakthrough therapy drug procedures 172
    - case studies 174
    - conditional approval procedures 172
    - EU process and timeline 119, 120
    - Japan new drug application (JNDA) 155
    - license renewal 173
    - new drug submission (NDS) 138
    - postapproval variations 196
    - postmarketing vigilance requirements 197
    - priority review and approval procedures 172
    - procedures in China 171, 172
    - procedures in Singapore 192, 193–196, 197
    - requirements and process 193–196
  - Marks, Peter W. 103
  - master cell banks (MCBs) 59
    - definition 218
    - product-specific challenges 73
  - materials
    - commercial manufacturing strategy 80
    - product-specific challenges 73
  - McCarty, Maclyn 3
  - McNeill, Lorrie H. 103
  - medical devices 36
  - Medical Devices Regulations (MDR) 129, 131, 134
  - Medical Products Administrations (MPAs) 165
  - Medical Services Advisory Committee (MSAC) 186
  - medicinal products. *See* advanced therapy medicinal products (ATMPs)
  - medicines. *See also* prescription medicines; prescription medicines
    - definition of 181
  - Medicines Act (NZ) 187
  - Medicines and Healthcare products Regulatory Agency (MHRA) 125
  - Medsafe 187
  - memoranda of understanding (MOUs) 150
  - Michigan 16
  - microbial vectors 55
  - Miescher, Friedrich 3
  - minimal manipulation 100, 131, 218
  - Missouri 16
  - mode of action (MOA)
    - biological product 30
    - definition of 30, 218
    - device 31
    - drug 31
    - primary. *See* primary mode of action (PMOA)
  - multi-luminance mobility test (MLMT) 43, 44
  - mutual acceptance of data (MAD) 151
  - mutual recognition agreements (MRAs) 150, 218
  - mycoplasma tests 66
- N**
- National Academies of Sciences, Engineering, and Medicine (US) 8
  - National Academy of Sciences (US) 13
  - National Bioethics Advisory Committee (NBAC) 6
  - National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (US) 14
  - National Competent Authority (NCA) 6
  - National Conference of State Legislatures (US) 6
  - National Essential Drug List (NEDL) 174

- National Health Act (Australia) 186
  - National Healthcare Security Administration (NHSA) 164, 174
  - National Health Commission (NHC) 163, 164
  - National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) 76
  - National Institute of Standards (NIST) 76, 77
  - National Institutes for Food and Drug Control (NIFDC) 164
  - National Institutes of Health (NIH) 76
    - fetal tissue research policy 17
    - guidelines 13
    - Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) 9, 13, 14, 17
    - Human Embryo Research Panel 14
    - Human Fetal Tissue Research Ethics Advisory Board 17
    - Human Fetal Tissue Transplantation Research Panel 14
    - Office of Recombinant DNA Activities (ORDA) 12
    - Recombinant DNA Molecule Program Advisory Committee (RAC) 9, 12, 14
    - research funding 49, 50
  - National Medical Products Administration (NMPA) 163, 164, 171
  - National Reimbursement Drug List (NRDL), 174
  - National Research Act (US) 14
  - new drug submission (NDS) 138
  - New England Journal of Medicine* 17
  - new organisms 188
  - New Substances Notification (NSN) Regulations (Organisms) 134
  - New Zealand (NZ) 187, 188
    - Current Guidelines on the Regulation of Therapeutic Products in New Zealand 187
    - Environmental Protection Authority (EPA) 188
    - Gene Technology Advisory Committee (GTAC) 187
    - legislation 187
  - next generation sequencing (NGS) 82
  - NIH Revitalization Act (US) 14
  - nonclinical studies
    - good laboratory practice (GLP) 150
    - Japanese Ministerial Ordinance 151
    - non-GLP proof-of-concept studies 52
    - Non-Satisfactory Notice (NSN) 137
    - non-viral vectors 50
    - No Objection Letter (NOL) 137
    - no observed adverse effect levels (NOAELs) 52
    - Norway 124
    - notice of compliance with conditions (NOC/c) 138
    - Novartis 17, 135
    - Novartis Gene Therapies 130
    - Novartis Pharmaceuticals 130, 180
    - Novel and Exceptional Technology and Research Advisory Committee (NExTRAC) 13, 17
    - NR082 ophthalmic injection 164
    - nusinersen (Spinraza) 130
- O**
- Obama, Barack 8, 16, 17
  - Office for Human Research Protections 12
  - Office of Blood Research and Review (OBRR) 18
  - Office of Cellular, Tissue, and Gene Therapies (OCTGT) 18
  - Office of Combination Products (OCP) 14, 32
  - Office of Policy and International Collaboration (OPIC) 131
  - Office of Recombinant DNA Activities (ORDA) 12
  - Office of the Gene Technology Regulator (OGTR) 177
    - cell and gene therapy product licenses 186
    - dealings involving intentional release (DIR) licenses 185
    - dealings not involving intentional release (DNIR) licenses 185, 186
    - license requirements 178
  - Office of Tissues and Advanced Therapies (OTAT) 6, 16, 18, 49
    - Division of Cellular and Gene Therapies (DCGT) 102, 105
    - organizational structure 104
  - Office of Vaccines Research and Review (OVRR) 18
  - off-target effects 26
  - off-the-shelf products 72
    - challenges 73

- suggested points to consider 82
  - Oh, Steven 105
  - onasemnogene abeparvovec-xioi (Zolgensma) 130, 186
  - Oncorine 163, 174
  - on-site evaluation (OSE) 138
  - on-target off-tumor toxicity 26
  - optimization 40, 75
  - Organization for Economic Cooperation and Development (OECD) 151
  - orphan drug programs 139
  - Ortho-ACI chondrocytes 180, 182
  - Orthocell Ltd. 180
  - Osiris Therapeutics 130
- P**
- packaging 80
  - patient preferences 43–44
  - patient registration system 159
  - peptide vaccines 73
  - peripheral blood mononuclear cells (PBMCs) 59
  - Pharmaceutical Affairs Act (PAA) 155
  - Pharmaceutical Affairs Law (PAL) 5, 144, 147
  - Pharmaceutical and Medical Devices Agency (PMDA) 5, 6
    - consultation process 143
    - consultations and meetings 152
  - Pharmaceutical and Medical Devices (PMD) Act (Japan) 144, 147, 153, 156, 159
  - Pharmaceutical Benefits Advisory Committee (PBAC) 186
  - Pharmaceutical Management Agency of NZ (PHARMAC) 187
  - Pharmaceutical Regulatory Information System (PRISM) 199
  - Pharmaceuticals, Medical Devices and Other Therapeutic Products Act (PMD Act) 5, 6
  - Phase 1 trials 49
  - Phase 2 trials 49
  - Phase 3 trials 49
  - phased trials 154
  - Phase III or licensing trials 78
  - pilot studies 52
  - plasmids 218
  - plasmid vectors 73
  - pluripotent stem cells (PSCs). *See* induced pluripotent stem cells (iPSCs)
  - polymerase chain reaction (PCR) 218
  - postapproval change management 173
  - postmarketing surveillance (PMS) 156–158
  - potency 25
  - potency testing 25
    - FDA guidance 55
    - US regulation 108
  - pre-BLA meetings 105
  - precision 204
  - preclinical assessment
    - current trends 51
    - good laboratory practice (GLP) 150
    - key suggestions or recommendations 52
    - US regulations 109
  - pre-IND meetings 104
  - pre-request for designation (pre-RFD) 32
  - Prescription Drug User Fee Act VII (PDUFA VII) 17
  - prescription medicines
    - Australian Register of Therapeutic Goods (ARTG) 186
    - facilitated review pathways 182, 184
    - regulation in Australia 181–185
    - standard review pathway 182
    - TGA review pathways 178, 179
  - prescription only medicines 181
  - President’s Council on Bioethics
    - “Cloning Human Beings” 8
    - formation 7, 15
  - primary mode of action (PMOA) 30
    - definition 218
    - determination by OCP 34
    - regulatory definition 32
  - PRIME (PRIority MEdicines) 55, 218
  - priority review 139
  - priority review and approval procedures 172
  - Prochymal (Human Adult Stem Cells) 130
  - product consultation 192
  - production 80
  - Project Orbis 125, 185, 219
  - proof-of-concept studies 52
  - protocols 219
  - Provenge 72
  - Public Health Service (PHS) Act (US) 6
    - Section 351 99
    - Section 361 4, 15, 16, 99
  - public scrutiny 11
  - Purohit-Sheth, Tejashri 104

**Q**

- QbD approach 82
- quality by design (QbD) 219
- quality control
  - commercial manufacturing strategy 80
  - regulations in China 166
- quality target product profile (QTTP) 40, 219

**R**

- Rabb, Harriet 6, 15
- rapid microbial methods 66
- rare diseases, gene therapy for 54, 111
- rDNA technology 10
- readiness, CMC 72, 78
- reagents 107
- RECELL 72
- Recombinant DNA Molecule Program Advisory Committee (RAC)
  - creation 9
  - enhanced gene therapy review 11
  - Human Gene Therapy Subcommittee (HGTS) 10, 11, 12
  - mandate 9
  - reduction and dissolution 12
  - second generation 10
  - third generation 10
  - timeline 14
- recombinant DNA (rDNA) 9
- regenerative medical products
  - definition of 5, 147
  - Japanese application and review process 155, 156
- Regenerative Medicine Advanced Therapy (RMAT) designation 55, 100–101
  - definition 219
  - development timeline 17
  - devices used with RMAT products 102
  - RMAT meetings 105
- Regenerative Medicine Promotion Act (Japan) 144
- regenerative medicines (RM)
  - Class I 146
  - Class II 146
  - Class III 146
  - combination products 29–36
  - definition of 4, 71, 219
  - distribution of medicines 85–96
  - EU regulation 117–126

- future directions 203–207
- history of 3–21
- logistics lanes 85, 87, 96
- manufacturing of 1
- regulation in Singapore 191
- regulatory frameworks 6
- risk-based classification of 145, 146
- standards development 76
- types of products 1
- unique properties of 23–26
- US regulation 99–115
- registration
  - Australian Register of Therapeutic Goods (ARTG) 178, 180, 182, 186
  - Drug Registration Regulation (DRR) 171
  - fees and timelines 196
  - Final Rule for Clinical Trials Registration and Results Information Submission (HHS) 12
  - Human Cell and Tissue Establishment Registration (FDA) 59
  - Institutional Biosafety Committee Registration Management System (IBC-RMS) 13
  - patient registration databases 159
  - registered products 164
  - registered protocols 12
  - retention of 196
  - safety registration databases 13
- regulation
  - manufacturing. *See* chemistry, manufacturing, and controls (CMC); *See* manufacturing controls
  - Regulation (EC) No 726/2004 4, 6, 119
  - Regulation (EC) No 1394/2007 4, 6, 117
- regulatory frameworks
  - Canadian 129–130
  - current trends 51–54
  - EU 117–126
  - evolution of 206
  - future directions 206
  - Japan 143–160
  - logistics 86–89
  - US 14–17, 99–115
  - US, EU, and Japan 6, 19
- regulatory professionals 205
- regulatory review
  - expedited pathways 45
  - hurdles during 43–44

regulatory science (RS) strategy consultations 152

release testing  
 considerations for 65  
 samples for 66

Relma-cel 174

replication competent retrovirus (RCR) 112

requests for designations (RFDs)  
 for combination products 32–33  
 required information 34

Research Portfolio Online Reporting Tools (RePORT) 219

RESTOBA 180

retinal disorders, gene therapy for 54

retroviral vector-based human gene therapy products 55

Ricles, Laura 105

risk assessment 93, 114

risk assessment and risk management plans (RARMPs) 185

RNA editing 24

Rosenberg, Steven 11

## S

safety, long-term 112–113

Safety of Human Cells, Tissues, and Organs for Transplantation Regulations (CTO Regulations) 129, 130, 131, 132, 135

safety reporting 199

scaffolds 219

Schultz, Kimberly 105

serious adverse events (SAEs)  
 definition 219  
 reporting 197, 198  
 unexpected serious adverse drug reactions (USADRs) 199

severe combined immune deficiency (SCID) 11

Shanghai Sunway Biotech Co., Ltd 163

Shanghai Xinzhi 164

shelf-life  
 of allogeneic therapies 92, 93  
 of autologous therapies 91, 92  
 of fresh finished products 91

*Sherley v. Sebelius* 16

shipping and handling  
 product-specific challenges 73  
 transport of starting cells or tissue 60–61

shipping labels  
 EU tissues and cells directives 88  
 example 88  
 GMO shipments 92

SiBiono GeneTech Co. Ltd. 163

Singapore  
 chemistry, manufacturing, and controls 197  
 clinical trial applications 198, 200, 201  
 CTGTP registration 196  
 dealer's license 200  
 good manufacturing practice (GMP) 198  
 Health Products (cell, tissue, and gene therapy products) Regulations 2021 191  
 Health Products (Clinical Trials) Regulations 198  
 Health Sciences Authority (HSA) 191, 192, 193, 196, 199  
 marketing authorization application requirements and process 193–196, 197  
 marketing authorization pathways 192  
 postmarketing vigilance requirements 197  
 registration fees and timelines 196  
 regulatory environment 191–200  
 requirements for safety reporting 199  
 special access routes (SARs) 201

Single European Code (SEC) 58, 60, 61

Sista, Ramani 104

somatic cell therapy 10  
 definition of 23  
 US regulation of 107

somatic cell therapy medicinal products (SCTPs)  
 classification of 4, 122  
 definition 219  
 legal definition 121

Spark Therapeutics 17, 130, 135

Special Access Program (SAP) 139, 219

special access routes (SARs) 201

Spink, Katy 205, 207

Spinraza (nusinersen) 130

spray on cells 72

Standard Coordinating Body (SCB) 77

standards development 76

starting materials  
 EU requirements 123  
 human cell or tissue-based 57–62  
 manufacturing factors 25  
 special considerations 57–62  
 traceability 124  
 transport 60–61



Stem Cell Research Enhancement Act (US) 15  
stem cells  
  definition 220  
  embryonic. *See* embryonic stem cells (ESCs)  
  engineered 216  
  first human trials 16  
  induced. *See* induced pluripotent stem cells (iPSCs)  
  therapeutic product types 73  
sterility testing  
  culture-based 66  
  samples for 67  
storage  
  of advanced therapy investigational medicinal products) 86  
  cryopreservation 64  
  EU GMP guidance for advanced therapy medicinal products 88  
  EU tissues and cells directives 87  
  of frozen regenerative medicines 94  
storage facilities  
  for allogeneic therapies 92, 94  
  need for 92, 94  
supply chains  
  of allogeneic therapies 93  
  of autologous therapies 90  
  of gene therapies 95  
Sweden 150  
Switzerland 150

## T

talimogene laherparepvec (Imlygic) 183  
target product profile (TPP) 40  
T-Cells 180  
Tecartus™ (brexucabtagene autoleucel) 65, 130, 182  
technical documents. *See* common technical document (CTD)  
temperature conditions  
  for allogeneic therapies 92, 93  
  for autologous therapies 91, 92  
terminology 4, 164  
TheraCys 72  
therapeutic dose selection 41  
Therapeutic Goods Act (Australia) 177, 181  
Therapeutic Goods Administration (TGA) 177, 178, 179  
Thomson, James 6, 15

tisagenlecleucel (Kymriah®) 65, 130, 180, 182  
tissue-engineered products (TEPs)  
  classification of 4, 122  
  definition 220  
  legal definition 121  
tissue establishments 58–59  
tissue labeling 60  
tissue products  
  labeling requirements 60  
  regulatory environment in Singapore 191–200  
Tissue Reference Group (TRG) 14, 102, 220  
tissue rules (FDA) 11  
tissue therapy regulations 10  
toxicity, on-target off-tumor 26  
traceability 89  
  considerations for 58  
  definition of 220  
  EU requirements 87, 124  
  example tracking portal status information 89  
tracking devices 89  
transforming principle 3  
transport  
  from procurement site to manufacturing site 60–61  
  shipping labels 88  
  of starting cells or tissue 60–61  
21st Century Cures Act (US) 4, 6, 17, 99, 100–101  
Type 1 use 149, 153  
Type 2 use 149  
Type A meetings 103  
Type B meetings 102, 103  
Type C meetings 103

## U

unexpected serious adverse drug reactions (USADRs) 199  
United Kingdom (UK)  
  clinical trials regulation 126  
  medicines regulation 117, 125  
United States (US)  
  Clinton Administration 6, 15  
  current state laws for embryonic stem cell and cloning research 7  
  development timeline of guidances, regulations, and laws 14–17  
  Guideline for Human Embryonic Stem Cell Research 8

- Obama Administration 16
    - President's Council on Bioethics 7, 15
    - regulation of combination products 29
    - regulation of regenerative medicine 4, 6, 14–17, 19, 99–115
  - Untitled Letters (FDA) 102
  - US Department of Defense (DOD) 76
  - US Department of Health and Human Services (HHS)
    - Final Rule for Clinical Trials Registration and Results Information Submission 12
    - policies 17
  - US Food and Drug Administration (FDA) 6, 12, 13
    - Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products 10
    - Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 106
    - Center for Biologics Evaluation and Research (CBER) 18, 49
    - clinical trials for human stem cell therapy 16
    - definition of combination products 29
    - definition of gene therapy 23
    - developmental timeline 13, 14, 15, 16, 17
    - draft guidance documents 77
    - enforcement actions 102
    - expedited review pathways 45
    - first FDA-approved AAV gene therapy 43
    - good tissue practices (GTPs) 57
    - Guidance for Industry Points to Consider in Human Somatic Cell Therapy and Gene Therapy 10
    - Human Cell and Tissue Establishment Registration website 59
    - meeting formats 106
    - meeting preparation 106
    - meetings 102–103
    - Office of Combination Products (OCP) 32
    - Project Orbis 125, 219
    - regulatory framework 99
    - requirements for CMC 54
    - requirements for comparability studies 75
    - suggested guidance documents 82
    - Tissue Reference Group (TRG) 102
    - tissue rules 11
    - Untitled Letters 102
    - Warning Letters 16
  - US Pharmacopeia (USP) 76, 136
- V**
- Varmus, Harold 12, 13
  - vectors
    - definition 220
    - design for gene therapy 40
    - testing 112
  - Verdun, Nicole 103
  - verification 149
  - viral testing 108
  - viral vectors 50
  - voretigene neparvovec-rzyl (Luxturna) 130, 186
- W**
- Weinberger, Caspar W. 9
  - Wei, Zexi 163
  - Wilmut, Ian 5
  - Wolff, CF 3
  - working cell banks (WCBs) 59, 220
  - World Health Organization 19
- X**
- xenotransplant products 73
- Y**
- Yescarta® (axicabtagene ciloleucel) 17, 65, 72, 130, 135, 138, 174, 182
- Z**
- Zimmerman review 187
  - Zolgensma (onasemnogene abeparvovec-xioi) 17, 130, 135, 186